ALYREF and ovarian cancer: We also suggest that the regulatory relationship described in this work between ALYREF and MYCN may extend to other human cancer types with high MYC/MYCN dependency (medulloblastoma, retinoblastoma, hematologic malignancies, glioblastoma, ovarian cancer, Wilms’ tumor, neuroendocrine prostate cancer).